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Costs associated with MRSA nares 
screens may be offset by the avoidance 
of unnecessary empiric anti-MRSA 
therapy, associated therapeutic mon-
itoring, and potential adverse effects. 
Multiple studies have demonstrated a 
decrease in anti-MRSA therapy, serum-
level monitoring, and costs with using 
MRSA nares screens [4, 5]. In addition, 
many healthcare facilities already utilize 
MRSA screens for infection prevention 
and control measures. Such institutions 
can collaborate with their infection con-
trol program and utilize MRSA nares 
screens for antimicrobial stewardship 
efforts, as well.
While it has been suggested that risk 
factors may be the optimal choice to drive 
therapy decisions, we would argue the 
performance of predisposing risk factors 
and clinical prediction models or risk 
scores for MRSA fall short, compared 
to nasal screens, in their predictive per-
formance, as demonstrated in multiple 
studies [6, 7]. This can be partly attrib-
uted to both the relatively infrequent 
incidence of MRSA infection and the 
often non-specific nature of risk factors. 
Therefore, we believe nasal screens have 
strong and consistent clinical utility in 
the right prescribing setting.
An aim of antimicrobial stewardship 
programs is to minimize the inappro-
priate and unnecessary use of antibiotics 
and their associated adverse outcomes 
(ie, toxicities, resistance, and cost). 
Similar to incorporating any antimicro-
bial stewardship tool, including other 
rapid diagnostic tests, institutions should 
evaluate the potential value from utiliz-
ing MRSA nares screens for improving 
patient care.
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Use of Prophylactic Antibiotics 
in Aspiration Pneumonia
To the Editor—We read with great inter-
est the recent article by Dragan et  al [1]. 
A total of 200 cases (76 used prophylactic 
antibiotics and 124 did not) were included 
in their study, and they reported that the 
use of prophylactic antibiotics was of no 
benefit in aspiration pneumonia  (AP). 
AP means anaerobic pneumonia. For this 
reason, it is absolutely necessary to use 
anaerobic-spectrum antibiotics in AP. 
In their study, 35 cases in the antibiotic 
group received ceftriaxone monotherapy, 
but there is no anaerobic effect of ceftriax-
one monotherapy. This amount is almost 
half that of the prophylaxis group (n = 35, 
46%). Therefore, the antibiotic prophylaxis 
group of the study had to be evaluated in 
(76 − 35 = 41) 41 patients. Consequently, 
the results of the study should be inter-
preted with caution. If all the patients in 
the prophylaxis group had received appro-
priate antibiotics, the results could be very 
different. We think that the published 
results do not reflect a real-life situation.
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Reply to Karabay and Karabay
To the Editor—We thank Karabay et al 
for their interest in our study, in which we 
found no clinical benefit of antimicrobial 
prophylaxis compared to supportive care 
for the first 48 hours following an epi-
sode of clearly documented macroaspi-
ration causing pneumonitis [1]. In their 
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